<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40345">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105623</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2013-09</org_study_id>
    <nct_id>NCT02105623</nct_id>
  </id_info>
  <brief_title>EARly Prevention of aTHeroma Progression</brief_title>
  <acronym>EARTH</acronym>
  <official_title>EARly Prevention of aTHeroma Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare standard therapy (risk factor control, life style
      modification) versus standard therapy plus low-dose rosuvastatin therapy (5mg/day) on
      progression of coronary atherosclerosis in statin naive individuals who have mild CAD
      (nonobstructive coronary atherosclerotic plaques) and normal LDL (low-density lipoprotein)
      cholesterol levels(〈130mg/dl).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent change in total atheroma volume(TAV)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in total atheroma volume(TAV) at region of interest defined as(TAV at 24 months-TAV at baseline)/(TAV at baseline)x 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PAV(Percent atheroma volume) at region of interest</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in PAV(Percent atheroma volume) at region of interest(PAV at 24months-PAV at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall TAV</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sum of TAV in all coronary segments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TAV at region of interest</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
    <description>TAV at 24months-TAV at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall CAC(coronary artery calcification) score</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
    <description>overall CAC score at 24months-overall CAC score at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of segment of any coronary atherosclerotic plaques</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in lipid levels</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risk factor control Diet Exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risk factor control Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Risk factor control Diet Exercise for 24months</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Risk factor control rosuvastatin 5mg/day for 24months</description>
    <arm_group_label>Rosuvastatin therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at least 35 years of age

          -  Mild CAD (nonobstructive coronary atherosclerotic plaques, lumen narrowing &lt;50%) and
             CAC score &lt;300 in at least one segment of proximal or mid-portion of major epicardial
             coronary arteries

          -  LDL cholesterol &lt;130mg/dl

        Exclusion Criteria:

          -  History of stable angina, or acute coronary syndrome

          -  History of transient ischemic attack, or stroke

          -  Chronic kidney disease (eGFR&lt; 60ml/min)

          -  Diabetes mellitus with microvascular complications or insulin therapy

          -  Hypertriglyceridemia (triglyceride &gt;500mg/dl)

          -  Any statin therapy in the past 4 weeks

          -  Planned cardiac surgery or planned major non-cardiac surgery within 6 months.

          -  Chronic disease requiring treatment with oral, intravenous, or intra-articular
             corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).

          -  A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in
             the past 3 years or current treatment for the active cancer.

          -  Any clinically significant abnormality identified at the screening visit, physical
             examination, laboratory tests, or electrocardiogram which, in the judgment of the
             Investigator, would preclude safe completion of the study.

          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation
             (ALT or AST &gt; 3 times upper limit of normal).

          -  History of adult asthma manifested by bronchospasm in the past 6 months, or currently
             taking regular anti-asthmatic medication(s).

          -  Unwillingness or inability to comply with the procedures described in this protocol.

          -  Positive pregnancy test (all female subjects of childbearing potential must have a
             urine ß-human chorionic gonadotropin(hCG) pregnancy test performed at Screening and/
             or within 7 days prior to randomization) or is known to be pregnant or lactating.

          -  Hypersensitivity to Crestor

          -  Skeletal muscle disease

          -  Combination use with cyclosporine

          -  Galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption

          -  Combination use of protease inhibitor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheol-whan Lee, MD</last_name>
      <email>cheolwlee@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jung-hee Ham, Research coordinator</last_name>
      <email>cvcrc5@amc.seoul.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Cheol-whan Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>April 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Coronary Arteriosclerosis</keyword>
  <keyword>rosuvastatin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
